(Q33389625)

26 July 2017

1 reference

title

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma (English)

1 reference

26 July 2017

Shannon M Kavanaugh

1

1 reference

26 July 2017

Lisa A White

series ordinal

2

1 reference

26 July 2017

Jill M Kolesar

series ordinal

3

1 reference

26 July 2017

publication date

1 May 2010

1 reference

American Journal of Health-System Pharmacy

26 July 2017

published in

1 reference

26 July 2017

volume

67

1 reference

26 July 2017

issue

10

1 reference

26 July 2017

page(s)

793-797

1 reference

Cutaneous T-cell lymphoma

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

31 March 2020

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Histone deacetylase inhibitors: molecular mechanisms of action

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Histone acetylation and transcriptional regulatory mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

31 March 2020

Epigenetics and cancer

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP090247

31 March 2020

Identifiers

DOI

10.2146/AJHP090247

1 reference

26 July 2017

1 reference